Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 294Triple Negative Breast Neoplasms 50Inflammatory Breast Neoplasms 19Breast Neoplasms, Male 18Neoplasm Metastasis 11Neoplasms 10Cardiotoxicity 8Ovarian Neoplasms 5Sarcoma 4Lymphoma, Non-Hodgkin 4Carcinoma, Ductal, Breast 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Invasive Breast Cancer 3Colorectal Neoplasms 3Breast Diseases 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pathologic Complete Response 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neutropenia 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2

Interventions

Docetaxel 4Epirubicin 3Cyclophosphamide 3Paclitaxel 2Vinorelbine 1Tamoxifen 1Iodine-123 1Fluorouracil 1Doxorubicin 1Carboplatin 1CP protocol 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Breast Cancer × Doxorubicin × Breast × Clear all
NCT00793377 2008-11-19

Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Docetaxel (AC-Doc) Versus Dose-Dense Doxorubicin and Docetaxel (ADoc) in Breast Cancer

GBG Forschungs GmbH

Phase 3 Completed
913 enrolled
Breast

Primary Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡